TRIAL DETAIL

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Drug:
Trial Name:
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
2
Start Date 11/01/2009
Age of Trial (yrs) 14.4
Treatment Phase:
Gleevec-resistant
Drug Category:
IGF1R inhibitor + mTOR Inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
CDR0000659358, MSKCC-09097
Sponsor:
Memorial Sloan-Kettering Cancer Center
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
From Clinical Trials.gov Disease Characteristics: Confirmation of IGF1R status in pre-existing tumor specimens by IHC.

From MSKCC website: Patients must have a confirmed diagnosis of locally advanced, recurrent, and/or metastatic sarcoma (soft tissue or bone) that contains the insulin-like growth factor 1 receptor. For an early part of the study, patients will be allowed to receive treatment regardless of whether their tumor tests positive or negative.

Trial Links

Trial Results

Drug Information

CCI-779 (temsirolimus) in Wikipedia
 

Trial Sites

Name
Address
City
State
Zip
Country
1275 York Ave
New York
NY
10065
USA
5841 S. Maryland Ave
Chicago
IL
60637
USA